Abstract
There is a paucity of therapies for most neurological disorders-from rare lysosomal storage diseases to major public health concerns such as stroke and Alzheimer's disease. Advances in the targeting of drugs to the CNS are essential for the future success of neurotherapeutics; however, the delivery of many potentially therapeutic and diagnostic compounds to specific areas of the brain is restricted by the blood-brain barrier, the blood-CSF barrier, or other specialised CNS barriers. These brain barriers are now recognised as a major obstacle to the treatment of most brain disorders. The challenge to deliver therapies to the CNS is formidable, and the solution will require concerted international efforts among academia, government, and industry. At a recent meeting of expert panels, essential and high-priority recommendations to propel brain barrier research forward in six topical areas were developed and these recommendations are presented here.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 84-96 |
| Number of pages | 13 |
| Journal | The Lancet Neurology |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2008 |
Bibliographical note
Funding Information:The meeting on which this report was based was partially funded by an R13 grant from the National Institutes of Health (Grant 1 R13 CA86959-06). We would like to thank all of the people who attended the Strategies for Advancing Brain-Barriers Translational Research meeting (March 22–23, 2007), Stevenson, WA, USA and who contributed to the roundtable discussions ( webappendices 1 and 2 ). Special thanks to Nancy Doolittle, Leslie Muldoon, and Emily Hochhalter who were instrumental in the development of this report.
